卵巢癌中MDR1的表达及其临床意义

Expression of Multidrug Resistance Gene in Epithelial Ovarian Carcinoma and Its Clinical Significance

目的检测MDR1在卵巢癌中的表达并探讨其在卵巢癌化疗耐药中的作用。方法采用RT-PCR复合定量技术对40例卵巢癌、20例良性卵巢肿瘤、20例正常卵巢组织中MDR1的表达进行检测,分析其表达与临床病理特征及化疗疗效的相关性。结果卵巢癌中MDR1的表达显著高于正常组及良性肿瘤组,且肿瘤分化程度越差其表达越高,P<0.05。MDR1在术前化疗组中的阳性表达率显著高于术前未化疗组,P<0.05。MDR1阴性组患者的化疗反应率显著高于阳性组患者(70.6%比43.5%),P<0.05,MDR1阴性对化疗有效的预测值为70.6%。结论MDR1可能在卵巢癌获得性耐药的形成中发挥一定作用,MDR1的检测可能有助于卵巢癌化疗方案的制定,并成为预测化疗疗效的有用指标。

Objective To detect the expression of multidrug resistance gene （MDR1） in the epithelial ovarian carcinoma, and investigate its role in drug resistance. Methods The expression of MDR1 in 40 cases of ovarian carcinoma, 20 cases of benign ovarian tumor and 20 cases of normal control were determined by RT-PCR technique. The relations between MDR1 expression and the clinical-pathological characteristics as well as chemotherapeutic response were discussed. Results The positive expression rate of MDR1 in ovarian carcinoma was significantly higher than that in benign tumors and normal tissues, and a significant relationship was shown between its expression and pathologic differentiation, P〈0. 05. The MDR1 positive expression rate in cases received chemotherapy before surgery were significantly higher than in cases who didn＇t, P〈0. 05. The response rate in the MDR1 negative group was higher than that in the positive group （70. 6% vs 43.5 %）, P〈0. 05. The predictive value of negative MDR1 staining for objective response was 70. 6%. Conclusion These data suggested that MDR1 may play an important role in the acquired multidrug resistance of ovarian carcinoma. Determination of MDR1 expression may be useful for working out chemotherapy plan and predicting chemotherapeutic response of ovarian carcinoma patients.